{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T16:21:21Z","timestamp":1780417281604,"version":"3.54.1"},"reference-count":16,"publisher":"Elsevier BV","issue":"30","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,8,7]],"date-time":"2025-08-07T00:00:00Z","timestamp":1754524800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["jacc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JACC: Case Reports"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.jaccas.2025.105277","type":"journal-article","created":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T20:06:11Z","timestamp":1759349171000},"page":"105277","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Cardiogenic Shock in Hypertrophic Cardiomyopathy Treated With Mavacamten and Clarithromycin"],"prefix":"10.1016","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7632-666X","authenticated-orcid":false,"given":"Mohamad S.","family":"Alabdaljabar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Milind","family":"Desai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey B.","family":"Geske","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.jaccas.2025.105277_bib1","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.clpt.2004.10.002","article-title":"Inhibition of human intestinal wall metabolism by macrolide antibiotics: effect of clarithromycin on cytochrome P450 3A4\/5 activity and expression","volume":"77","author":"Pinto","year":"2005","journal-title":"Clin Pharmacol Ther"},{"issue":"4","key":"10.1016\/j.jaccas.2025.105277_bib2","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1002\/cpt.3005","article-title":"Physiologically based pharmacokinetic modeling and simulation of mavacamten exposure with drug-drug interactions from CYP inducers and inhibitors by CYP2C19 phenotype","volume":"114","author":"Chiang","year":"2023","journal-title":"Clin Pharmacol Ther"},{"issue":"10","key":"10.1016\/j.jaccas.2025.105277_bib3","first-page":"1266","article-title":"Drug-drug interactions: how scared should we be?","volume":"161","author":"Shapiro","year":"1999","journal-title":"CMAJ"},{"issue":"12","key":"10.1016\/j.jaccas.2025.105277_bib4","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1002\/pds.5691","article-title":"A meta-analysis assessing the prevalence of drug-drug interactions among hospitalized patients","volume":"32","author":"Aksoy","year":"2023","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"2","key":"10.1016\/j.jaccas.2025.105277_bib5","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1345\/aph.1P592","article-title":"Adverse drug reaction deaths reported in United States vital statistics, 1999-2006","volume":"46","author":"Shepherd","year":"2012","journal-title":"Ann Pharmacother"},{"issue":"23","key":"10.1016\/j.jaccas.2025.105277_bib6","doi-asserted-by":"crossref","first-page":"2324","DOI":"10.1016\/j.jacc.2024.02.014","article-title":"2024 AHA\/ACC\/AMSSM\/HRS\/PACES\/SCMR guideline for the management of hypertrophic cardiomyopathy: a report of the American Heart Association\/American College of Cardiology joint committee on clinical practice guidelines","volume":"83","author":"Ommen","year":"2024","journal-title":"J Am Coll Cardiol"},{"issue":"19","key":"10.1016\/j.jaccas.2025.105277_bib7","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1161\/CIRCULATIONAHA.124.072445","article-title":"Mavacamten in patients with hypertrophic cardiomyopathy referred for septal reduction: week 128 results from VALOR-HCM","volume":"151","author":"Desai","year":"2025","journal-title":"Circulation"},{"issue":"4","key":"10.1016\/j.jaccas.2025.105277_bib8","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1177\/10600280221117812","article-title":"Mavacamten, a first-in-class cardiac Myosin inhibitor for obstructive hypertrophic cardiomyopathy","volume":"57","author":"Dalo","year":"2023","journal-title":"Ann Pharmacother"},{"issue":"7","key":"10.1016\/j.jaccas.2025.105277_bib9","doi-asserted-by":"crossref","first-page":"e324","DOI":"10.1093\/ajhp\/zxae320","article-title":"Risk evaluation and mitigation strategy for mavacamten: an example demonstrating appropriate safety oversight","volume":"82","author":"Desai","year":"2024","journal-title":"Am J Health Syst Pharm"},{"issue":"9","key":"10.1016\/j.jaccas.2025.105277_bib10","doi-asserted-by":"crossref","first-page":"e206","DOI":"10.1093\/ajhp\/zxad338","article-title":"REMS: time to reevaluate","volume":"81","author":"Daujatas","year":"2024","journal-title":"Am J Health Syst Pharm"},{"issue":"1","key":"10.1016\/j.jaccas.2025.105277_bib11","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.124.012441","article-title":"Mavacamten: real-world experience from 22 months of the risk evaluation and mitigation strategy (REMS) program","volume":"18","author":"Desai","year":"2024","journal-title":"Circ Heart Fail"},{"issue":"47","key":"10.1016\/j.jaccas.2025.105277_bib12","doi-asserted-by":"crossref","first-page":"5071","DOI":"10.1093\/eurheartj\/ehae579","article-title":"Long-term effect of mavacamten in obstructive hypertrophic cardiomyopathy","volume":"45","author":"Garcia-Pavia","year":"2024","journal-title":"Eur Heart J"},{"issue":"10","key":"10.1016\/j.jaccas.2025.105277_bib13","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1007\/s40265-022-01739-7","article-title":"Mavacamten: first approval","volume":"82","author":"Keam","year":"2022","journal-title":"Drugs"},{"issue":"44","key":"10.1016\/j.jaccas.2025.105277_bib14","doi-asserted-by":"crossref","first-page":"4622","DOI":"10.1093\/eurheartj\/ehad637","article-title":"Mavacamten: a first-in-class myosin inhibitor for obstructive hypertrophic cardiomyopathy","volume":"44","author":"Braunwald","year":"2023","journal-title":"Eur Heart J"},{"issue":"10","key":"10.1016\/j.jaccas.2025.105277_bib15","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.1016\/j.hrthm.2024.04.055","article-title":"Incidence of newly recognized atrial fibrillation in patients with obstructive hypertrophic cardiomyopathy treated with mavacamten","volume":"21","author":"Castrichini","year":"2024","journal-title":"Heart Rhythm"},{"issue":"20","key":"10.1016\/j.jaccas.2025.105277_bib16","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1056\/NEJMoa2401424","article-title":"Aficamten for symptomatic obstructive hypertrophic cardiomyopathy","volume":"390","author":"Maron","year":"2024","journal-title":"N Engl J Med"}],"container-title":["JACC: Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666084925020583?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666084925020583?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T06:30:05Z","timestamp":1760077805000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666084925020583"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":16,"journal-issue":{"issue":"30","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["S2666084925020583"],"URL":"https:\/\/doi.org\/10.1016\/j.jaccas.2025.105277","relation":{},"ISSN":["2666-0849"],"issn-type":[{"value":"2666-0849","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cardiogenic Shock in Hypertrophic Cardiomyopathy Treated With Mavacamten and Clarithromycin","name":"articletitle","label":"Article Title"},{"value":"JACC: Case Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaccas.2025.105277","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier on behalf of the American College of Cardiology Foundation.","name":"copyright","label":"Copyright"}],"article-number":"105277"}}